High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy.

Rates of rifaximin treatment retention are low despite the known benefits of rifaximin use for breakthrough HE. High 30-day OOP cost is associated with reduced rifaximin treatment retention.